

Special Issue

Pros, Cons and Perspectives of SARS-CoV-2/COVID-19 Vaccines and Vaccination

Message from the Guest Editors

The need for an effective anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/coronavirus disease 2019 (COVID-19) vaccine has been clear since the beginning of the global pandemic, in early 2020. Within one year from SARS-CoV-2 identification, with hundreds of ad hoc vaccine studies carried out and tens of candidate vaccines advanced to clinical testing, a few novel vaccines have been approved for emergency use in humans. This unprecedented extraordinary scientific and financial effort has thrived on freely available basic science data, leading to the successful exploitation of innovative platforms against key viral targets. Nonetheless, several questions remain open as to whether the newly approved, or other yet-to-be-identified, vaccines will be able to control the COVID-19 pandemic and for how long, and whether vaccine safety will be acceptable in the long run.

Guest Editors

Dr. Flavia Ferrantelli

National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy

Dr. Chiara Chiozzini

National Center for Global Health, Istituto Superiore di Sanità, Rome, Italy

Deadline for manuscript submissions

closed (1 February 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/84405

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).